In 2014 the second quarter results have highlighted $19.5 billion as the ratio of total sales Johnson & Johnson has reached to. The negative impact of currency this year was 0.3 percent and the Operation results has managed to reach up to 9.4% in the second quarter. Domestically and internationally the sales were increased by 14.9% and 4.4%. This year in the second quarter the consumer division worldwide sales were $3.7 billion and this represents an increase of 2.4 percent, when compare to the prior year 2013 same quarter consisting of an operational increment of 3.6 percent.
“Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities,” said Alex Gorsky, Chairman and Chief Executive Officer.
Johnson & Johnson (J&J) this year in the second quarter has reported $4.31 billion net earning and $1.51 per diluted share. This quarter the net earnings have included a charge of approximately$0.5 billion, under the title of after-tax special items. The company has declared and increment in its earnings guidance for the year 2014 ranging from $5.85 – $5.92 per share. Johnson & Johnson has made $8.5 billion pharmaceutical sales in the second quarter of 2014 and in this segment the domestic and international sales were increased by 36.8 percent and 6.8 percent.
This year in the second quarter Jonhson & Johnson (J&J) has announced the plan they made for repurchasing stocks. The buy back plan for the common stocks of Johnson & Johnson was to buy back up to $5 billion. This quarter the company had repurchased 2.8226 billion common stocks outstanding. Johnson & Johnson (J&J) have declared 70 cents per share dividend on the company’s common stock for the third quarter. Today the stock market has highlighted $107.15 to be the share price for today, with the price change of $0.05 or 0.05%. The previous closed price for Johnson & Johnson was $107.10. The day’s high price for the stocks is $107.49 and the lowest value is $106.20, on weekly evaluation the highest price for 52 weeks is $108.77 and lowest is $85.50. The Market cap highlighted by the stock market for J&J is $302.05B, with the P/E ratio of 19.44.
“Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues’ position us well in this evolving and dynamic global health care market.”